Paper presentation on Impect assessment of rota virus vaccine on acute gastroenteritis and it's safety with focus on intussuception for pedia resident
Asking for Preferences
Reading File
Searching PubMed
rotavirus vaccine efficacy acute gastroenteritis children
Searching PubMed
rotavirus vaccine intussusception risk safety
Searching the Web
rotavirus vaccine global impact acute gastroenteritis mortality reduction 2024 WHO
Reading Article
Reading Article
Reading Article
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Your presentation is ready:
Rotavirus Vaccine Impact Peds
Presentation · PPTX
What's inside — 15 slides
| # | Slide | Key content |
|---|---|---|
| 1 | Title slide | Dark navy/teal design, full title |
| 2 | Outline | Numbered roadmap for the talk |
| 3 | Global Disease Burden | ~528,000 → ~215,000 deaths/yr; 30–70% of AGE hospitalizations pre-vaccine |
| 4 | The Vaccines | RV1 (Rotarix) vs. RV5 (RotaTeq) — side-by-side comparison of schedule, composition, manufacturer |
| 5 | Mechanism of Action | Gut mucosal sIgA induction, memory response, immunogenicity-protection correlation (R² = 99.7%) |
| 6 | Global AGE Impact | 67% reduction in RV hospitalizations; breakdown by low/medium/high-mortality countries |
| 7 | US-Specific Impact | 60–90% hospitalization reduction; 177k hospitalizations + 242k ED visits averted/year |
| 8 | Meta-Analysis Table | JAMA Pediatr 2021 (PMID 33970192) — RR/OR data for all major vaccines; no serious AEs |
| 9 | Intussusception Background | Definition, peak age, diagnosis, baseline rate ~1–3/1,000; why it matters for vaccine safety |
| 10 | RotaShield Lesson | 1999 withdrawal story; ~1/10,000 risk; how it shaped RV1/RV5 trial design |
| 11 | Post-Licensure Surveillance | Split view: countries with NO signal vs. those detecting 1–5 excess cases/100,000; risk window |
| 12 | Risk–Benefit Analysis | Head-to-head table — intussusception risk vs. lives and hospitalizations saved |
| 13 | Contraindications & Precautions | History of intussusception, SCID, age cutoffs, immunocompromised management |
| 14 | Global Deployment & WHO | 120+ countries, WHO 2021 position, China 2024 consensus, Rotavac/Rotasiil in Asia/Africa |
| 15 | Take-Home Messages | 7 numbered key points for residents to remember |
Key sources cited throughout:
- Red Book 2021 (AAP Committee on Infectious Diseases)
- Sun et al., JAMA Pediatrics 2021 (PMID: 33970192) — 20 RCTs + 38 case-control studies
- Henschke et al., Vaccine 2022 (PMID: 35184924) — high-mortality settings
- Gidengil et al., Vaccine 2021 (PMID: 34049735) — US routine immunization safety review
- Sleisenger & Fordtran's GI & Liver Disease; Rosen's Emergency Medicine
This is a shared conversation. Sign in to Orris to start your own chat.